drugset
drugset / Trial / NCT05905484

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

NCT05905484 ↗

Phase 1 Completed 35 enrolled Atea Pharmaceuticals, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

Timeline

Start
2023-04-25
Primary completion
2023-05-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified — Oral
Comparator Moxifloxacin Small molecule — Oral

Indications

No indication recorded.